Leshchinskii L A, Odnopozov I I, Valeeva R M, Kochubeeva O V, Samartsev D B, Tubylova N A, Mul'manovskii B L
Ter Arkh. 1995;67(12):13-7.
349 chronic sufferers from coronary heart disease (functional class II-IV) were exposed to He-Ne laser radiation, received alpha-tocopherol acetate, solcoseryl, mildronate. Alleviation of pain syndrome, quicker increase of exercise tolerance were observed in patients treated with combined regimens: i.v. laser radiation+alpha-tocopherol acetate, i.v. laser therapy+alpha-tocopherol acetate+solcoseryl. Solcoseryl proved efficient against arrhythmia, positive trends in lipid peroxidation were observed in the use of preradiation antioxidants. It is thought valid to use drug "protection" in laser therapy of CHD, especially in growing intensity of the exposure and power of the beam, to control parameters of coagulation, hemostasis, microcirculation and lipid peroxidation.
349名冠心病慢性患者(功能分级为II-IV级)接受了氦氖激光照射,并服用了醋酸α-生育酚、舒康博和米多君。在采用联合治疗方案的患者中观察到疼痛综合征减轻、运动耐量更快提高:静脉激光照射+醋酸α-生育酚、静脉激光治疗+醋酸α-生育酚+舒康博。舒康博被证明对心律失常有效,在使用辐射前抗氧化剂时观察到脂质过氧化呈积极趋势。在冠心病的激光治疗中使用药物“保护”被认为是有效的,特别是在照射强度和光束功率不断增加的情况下,以控制凝血、止血、微循环和脂质过氧化的参数。